NOXCROS: The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

Sponsor
Florida State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06018480
Collaborator
(none)
10
1
2
20
0.5

Study Details

Study Description

Brief Summary

This research study seeks to determine the effects of an enzyme in the human body called NADPH oxidase (NOX) on blood flow. In addition, the study will investigate the benefits of creatine monohydrate, a common sports performance supplement, on blood food and vessel function. Participants will undergo two study arms, one in which they consume a high carbohydrate meal pre- and post-creatine monohydrate supplementation and one in which they will consume a high carbohydrate meal pre- and post-placebo supplementation. Blood flow and endothelial function will be assessed before and for 4 hours following the consumption of a high-carbohydrate meal pre and post-supplementation (creatine monohydrate and placebo).

Condition or Disease Intervention/Treatment Phase
  • Other: Creatine Monohydrate
  • Other: Maltrodextrin (Placebo)
N/A

Detailed Description

A double-blind cross-over placebo-controlled study design will be used to determine the extent to which NOX and creatine monohydrate supplementation influences skeletal muscle microvascular blood flow and endothelial function following the administration of a high carbohydrate meal in sedentary individuals with overweight/obesity. Participants will be initially screened through a telephone screening over the phone or through an electronic copy (Qualtrics survey) and upon meeting the inclusion criteria, will be scheduled for a baseline visit. At the baseline visits participants will go through an informed consent, background and medical history questionnaire alongside a DXA scan and indirect calorimetry. Subsequently, participants will undergo two main testing days, one will occur before supplementation (creatine monohydrate or placebo) and the other following five days of supplementation (creatine monohydrate or placebo). At the main testing days participants will have their resting blood flow and endothelial function assessed before and for 4 hours following the consumption of a high carbohydrate meal. Following the two main testing days in the first study arm, participants will then undergo a 4-week wash-out in which they will resume their normal behavior and stop taking the supplement they were provided. After the washout period, participants will come back and repeat the baseline visit and the two main testing days. The only difference is that participants will receive the other treatment that was not received the first time (creatine monohydrate or placebo). Which treatment the participant receives first or second will be at random.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
NADPH Oxidase Affects on Blood Flow After Administering a High Carbohydrate Meal Pre- and Post-creatine Monohydrate Supplementation.
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Apr 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Creatine Monohydrate Supplementation

Participants will be provided with 20 grams of creatine monohydrate per day (100 grams total) in sealed and unopened packages (5 grams in each package). Participants will be asked to complete their supplementation protocol (20 grams/day) by mixing 5 grams of creatine monohydrate powder into water 4 times a day or 10 grams of creatine monohydrate powder into water twice a day. This supplementation will occur after a baseline visit in which participants consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial. Following the 5 days of supplementation participants will come back and consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial.

Other: Creatine Monohydrate
The supplementation is the intervention.
Other Names:
  • AlzChem
  • Placebo Comparator: Placebo (Maltodextrin)

    Participants will be provided with 20 grams of maltodextrin (placebo) per day (100 grams total) in sealed and unopened packages (5 grams in each package). Participants will be asked to complete their supplementation protocol (20 grams/day) by mixing 5 grams of maltodextrin (placebo) into water 4 times a day or 10 grams of maltodextrin (placebo) powder into water twice a day. This supplementation will occur after a baseline visit in which participants consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial. Following the 5 days of supplementation participants will come back and consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial.

    Other: Maltrodextrin (Placebo)
    Placebo to Creatine Monohydrate

    Outcome Measures

    Primary Outcome Measures

    1. Reactive oxygen species (ROS) [Change from pre to post five days of creatine monohydrate supplementation at 0, 1, 2, 3, 4 hours post high carbohydrate meal]

      Reactive oxygen species as indicated by H2O2 concentration measured with microdialysis.

    2. Muscle blood flow [Change from pre to post five days of creatine monohydrate supplementation at 0, 1, 2, 3, 4 hours post high carbohydrate meal]

      Muscle microvascular blood flow as monitored with microdialysis

    3. Endothelial function [Change from pre to post five days of creatine monohydrate supplementation at 0, 1, 2, 3, 4 hours post high carbohydrate meal]

      Endothelial function as measured with brachial artery flow mediated dilation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Body Mass Index: 25.0-34.9 kg/m2

    • Sedentary; sedentary status will be defined as not performing purposeful exercise training more than 20 minutes per day three a week.

    • Currently residing in Tallahassee, Florida, or the surrounding area

    • Not taking any medication(s) that interfere with metabolism.

    • Not taking any antioxidant supplementation, at least four weeks before the study.

    • Not supplementing with creatine monohydrate, at least four weeks before the study.

    • Not smoking, vaping, or chewing tobacco and willing to refrain from smoking, vaping, and chewing tobacco throughout the entire study.

    • Are not pregnant or planning on becoming pregnant

    Exclusion Criteria:
    • Metabolic or cardiovascular abnormalities, gastrointestinal disorders, and any condition that interferes with metabolism or oxygen delivery/transport including:

    • Diagnosed cardiovascular diseases or previous myocardial infarction.

    • Uncontrolled hypertension (resting: above 140 mmHg systolic or 90 mmHg diastolic)

    • Diabetes (Type 1 or 2)

    • Uncontrolled thyroid conditions

    • Cigarette smoking: current cigarette smoker or those who quit within the previous 6 months.

    • Participants consuming supplements or medication known to impact metabolism.

    • Participants already consuming creatine monohydrate

    • Allergies or intolerance to foods included in the standardized and high carbohydrate meal.

    • Women that are pregnant or planning on becoming pregnant

    • Weight gain or loss > 10% of body weight during the past 6 months

    • Participants consume a vegan or vegetarian diet.

    • Non-English-speaking individuals, infants, children, teenagers, cognitively impaired adults individuals, and adults who are unable to consent will be recruited for the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Florida State University Tallahassee Florida United States 32306

    Sponsors and Collaborators

    • Florida State University

    Investigators

    • Principal Investigator: Paul Baker, MS, Florida State University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Paul Baker, Graduate Research Assistant, Florida State University
    ClinicalTrials.gov Identifier:
    NCT06018480
    Other Study ID Numbers:
    • STUDY00003857
    First Posted:
    Aug 30, 2023
    Last Update Posted:
    Aug 30, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Paul Baker, Graduate Research Assistant, Florida State University

    Study Results

    No Results Posted as of Aug 30, 2023